Follicular Lymphoma Epidemiology Forecast to 2030 with Focus on United States, Germany, Spain, Italy, France, United Kingdom and Japan – ResearchAndMarkets.com – Business Wire

DUBLIN–()–The “Follicular Lymphoma – Epidemiology Forecast to 2030” drug pipelines has been added to ResearchAndMarkets.com’s offering.

This ‘Follicular Lymphoma – Epidemiology Forecast – 2030’ report delivers an in-depth understanding of the historical and forecasted epidemiology of Follicular Lymphoma in the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

With the recent approval of Yescarta for indolent follicular lymphoma, CAR T cells appear promising for follicular lymphoma. Kymirah (Novartis) and Breyanzi (BMS) are the key CART therapy currently in the pipeline for treating patients with relapsed/refractory FL. There may be a specific group of follicular patients that may benefit most from this therapy.

The newer bispecific antibodies (Mosunetuzumab and Ordonextamab) appear to be a promising asset, with less toxicity and just easier administration access for patients.

Follicular Lymphoma: Epidemiology

The Follicular Lymphoma epidemiology division provides insights into the historical and current patient pool, along with the forecasted trend for every seven major countries. It helps recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the report also provides the diagnosed patient pool, trends, and assumptions.

Key Findings

The disease epidemiology covered in the report provides historical and forecasted Follicular Lymphoma epidemiology segmented as the Incident cases of Follicular Lymphoma, Grade-specific cases of Follicular Lymphoma, Age-specific cases of Follicular Lymphoma, and Stage-specific cases of Follicular Lymphoma. The report includes the incident scenario of Follicular Lymphoma in the 7MM covering the United States, EU5 countries (Germany, France, Italy, Spain, and the United Kingdom), and Japan from 2018 to 2030.

Country-wise Follicular Lymphoma Epidemiology

The epidemiology segment also provides the Follicular Lymphoma epidemiology data and findings across the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.

The total incident population of Follicular Lymphoma in the 7MM countries was estimated to be 35,737 cases in 2020.

As per the estimates, the United States had the largest incidence of Follicular Lymphoma in 2020. Among the EU5 countries, Germany had the largest incident population of Follicular Lymphoma with 3,710 cases, followed by the United Kingdom in 2020. On the other hand, Spain had the lowest incident population of 1,640 cases in 2020.

Scope of the Report

  • Follicular Lymphoma report covers a detailed overview explaining its causes, symptoms, classification, pathophysiology, diagnosis, and treatment patterns.
  • Follicular Lymphoma Epidemiology Report and Model provide an overview of the risk factors and global Follicular Lymphoma trends in the seven major markets (7MM: US, France, Germany, Italy, Spain, UK, and Japan).
  • The report provides insight into the historical and forecasted patient pool of Follicular Lymphoma in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan.
  • The report helps recognize the growth opportunities in the 7MM concerning the patient population.
  • The report assesses the disease risk and burden and highlights the unmet needs of Follicular Lymphoma.
  • The report provides the segmentation of the Follicular Lymphoma epidemiology by Incident cases of Follicular Lymphoma in the 7MM.
  • The report provides the segmentation of the Follicular Lymphoma epidemiology by Grade-specific cases of Follicular Lymphoma in the 7MM.
  • The report provides the segmentation of the Follicular Lymphoma epidemiology by the Age-specific cases of Follicular Lymphoma in the 7MM
  • The report provides the segmentation of the Follicular Lymphoma epidemiology by the Stage-specific cases of Follicular Lymphoma in the 7MM.

Key Topics Covered:

1. Key Insights

2. Report Introduction

3. Executive Summary of Follicular Lymphoma

4. Disease Background and Overview

4.1. Introduction

4.2. Types of Follicular Lymphoma

4.3. Sign and Symptoms

4.4. Causes

4.5. Staging and Grading

4.6. Genetic Landscape of Follicular Lymphoma

4.7. Pathophysiology

4.8. Diagnosis

4.9. Treatment

4.10. Guidelines

4.10.1. NCCN Guidelines for Patient with Follicular Lymphoma

4.10.2. ESMO Clinical Practice Guidelines for diagnosis, treatment, and follow-up: Newly diagnosed and relapsed follicular lymphoma

4.10.3. Japanese Society of Hematology (JSH) practical guidelines for Follicular lymphoma

5. Epidemiology and Patient Population

5.1. Key Findings

5.2. 7MM Total Incidence of Follicular Lymphoma

5.3. Epidemiology of Follicular Lymphoma

5.4. The United States

5.4.1. Incidence of Follicular Lymphoma in the United States

5.4.2. Grade-specific cases of Follicular Lymphoma in the United States

5.4.3. Age-specific cases of Follicular Lymphoma in the United States

5.4.4. Stage-specific cases of Follicular Lymphoma in the United States

5.5. EU5

5.5.1. Germany

5.5.1.1. Incidence of Follicular Lymphoma in Germany

5.5.1.2. Grade-specific cases of Follicular Lymphoma in Germany

5.5.1.3. Age-specific cases of Follicular Lymphoma in Germany

5.5.1.4. Stage-specific cases of Follicular Lymphoma in Germany

5.5.2. France

5.5.3. Italy

5.5.4. Spain

5.5.5. The United Kingdom

5.6. Japan

6. Organizations contributing towards the fight against Follicular Lymphoma

7. Case Reports

8. Patient Journey

9. KOL Views

10. Appendix

For more information about this drug pipelines report visit https://www.researchandmarkets.com/r/u77hdz